Jazz anxious to launch once-daily Luvox CR
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Jazz Pharmaceuticals anticipates launching its social anxiety and obsessive compulsive disorder drug in the first quarter despite an FDA request for clarification on chemistry, manufacturing and controls in an "approvable" letter received Dec. 21 - the second for controlled-release Luvox CR (fluvoxamine maleate). The firm added 125 sales reps in the fourth quarter in anticipation of approval. CEO Sam Saks acknowledges the launch could be delayed by six months if FDA requests more data, but is hopeful that "this issue can be resolved rapidly"...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.